# Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Study · id `cardio:ct-nct03983551` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03983551](<https://clinicaltrials.gov/study/NCT03983551>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03983551

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT03983551. Non-randomized; no masking; primary purpose treatment. Start 2016-03-01 (actual); primary completion 2018-02-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT03983551, source copy `cardio:ctgov-nct03983551-2019-06-14`, retrieved 2026-10-26)
- Started: 2016-03-01 (actual) (ClinicalTrials.gov record NCT03983551, source copy `cardio:ctgov-nct03983551-2019-06-14`, retrieved 2026-10-26)
- Primary completion: 2018-02-10 (actual) (ClinicalTrials.gov record NCT03983551, source copy `cardio:ctgov-nct03983551-2019-06-14`, retrieved 2026-10-26)
- Completion: 2018-02-28 (actual) (ClinicalTrials.gov record NCT03983551, source copy `cardio:ctgov-nct03983551-2019-06-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03983551-2019-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas
- Condition: Type 2 Diabetes Mellitus
- Condition: Proteinuria
- Intervention (Drug): Dipeptidyl Peptidase 4 Inhibitor
- Intervention (Drug): Sulfonylurea
- Lead sponsor: Changhua Christian Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Changhua Christian Hospital (`cardio:org-changhua-christian-hospital`)

## Provenance

Content hash: d66add7ff56888e7b06c7033aa3f74fedefa0fcb276b9ee32390bd58c3b026e4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
